122 related articles for article (PubMed ID: 9478943)
1. Evaluation of GAL4/TATA in vivo. Induction of transgene expression by adenovirally mediated gene codelivery.
Fang B; Ji L; Bouvet M; Roth JA
J Biol Chem; 1998 Feb; 273(9):4972-5. PubMed ID: 9478943
[TBL] [Abstract][Full Text] [Related]
2. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system.
Koch PE; Guo ZS; Kagawa S; Gu J; Roth JA; Fang B
Mol Ther; 2001 Mar; 3(3):278-83. PubMed ID: 11273768
[TBL] [Abstract][Full Text] [Related]
3. Gal4-VP16 and Gal4-AH increase the orientational and axial specificity of TATA box recognition by TATA box binding protein.
Kays AR; Schepartz A
Biochemistry; 2002 Mar; 41(9):3147-55. PubMed ID: 11863454
[TBL] [Abstract][Full Text] [Related]
4. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
5. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax.
Kagawa S; Pearson SA; Ji L; Xu K; McDonnell TJ; Swisher SG; Roth JA; Fang B
Gene Ther; 2000 Jan; 7(1):75-9. PubMed ID: 10680019
[TBL] [Abstract][Full Text] [Related]
6. Diminishing adenovirus gene expression and viral replication by promoter replacement.
Fang B; Koch P; Roth JA
J Virol; 1997 Jun; 71(6):4798-803. PubMed ID: 9151874
[TBL] [Abstract][Full Text] [Related]
7. A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins.
Braselmann S; Graninger P; Busslinger M
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1657-61. PubMed ID: 8446579
[TBL] [Abstract][Full Text] [Related]
8. In vivo transgene activation from an HSV-based gene therapy vector by GAL4:vp16.
Oligino T; Poliani PL; Marconi P; Bender MA; Schmidt MC; Fink DJ; Glorioso JC
Gene Ther; 1996 Oct; 3(10):892-9. PubMed ID: 8908503
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated regulable target gene expression in vivo.
Burcin MM; Schiedner G; Kochanek S; Tsai SY; O'Malley BW
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):355-60. PubMed ID: 9892637
[TBL] [Abstract][Full Text] [Related]
10. A new inducible adenoviral expression system that responds to inflammatory stimuli in vivo.
Cai G; Nie X; Guo P; Guan Z; Zhang J; Shen Q
J Gene Med; 2006 Dec; 8(12):1369-78. PubMed ID: 17133340
[TBL] [Abstract][Full Text] [Related]
11. Toward gene therapy of endometriosis: transductional and transcriptional targeting of adenoviral vectors to endometriosis cells.
Othman EE; Zhu ZB; Curiel DT; Khatoon N; Salem HT; Khalifa EA; Al-Hendy A
Am J Obstet Gynecol; 2008 Aug; 199(2):117.e1-6. PubMed ID: 18674655
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein.
Farmer G; Friedlander P; Colgan J; Manley JL; Prives C
Nucleic Acids Res; 1996 Nov; 24(21):4281-8. PubMed ID: 8932384
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus vector covalently conjugated to polyethylene glycol with a cancer-specific promoter suppresses the tumor growth through systemic administration.
Yao X; Yoshioka Y; Morishige T; Eto Y; Narimatsu S; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
Biol Pharm Bull; 2010; 33(6):1073-6. PubMed ID: 20522982
[TBL] [Abstract][Full Text] [Related]
14. Periocular triamcinolone enhances intraocular gene expression after delivery by adenovirus.
Park CY; Chuck RS; Cano M; Yew M; Nguyen V; Parker J; Mori K; Gehlbach PL
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):399-406. PubMed ID: 18172118
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of activated but not basal transcription by the acidic activation domain of VP16: evidence for transcriptional adaptors.
Berger SL; Cress WD; Cress A; Triezenberg SJ; Guarente L
Cell; 1990 Jun; 61(7):1199-208. PubMed ID: 2163758
[TBL] [Abstract][Full Text] [Related]
16. A Renilla luciferase-Aequorea GFP (ruc-gfp) fusion gene construct permits real-time detection of promoter activation by exogenously administered mifepristone in vivo.
Yu YA; Szalay AA
Mol Genet Genomics; 2002 Oct; 268(2):169-78. PubMed ID: 12395191
[TBL] [Abstract][Full Text] [Related]
17. GAL4 derivatives function alone and synergistically with mammalian activators in vitro.
Lin YS; Carey MF; Ptashne M; Green MR
Cell; 1988 Aug; 54(5):659-64. PubMed ID: 3044607
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
Kühnel F; Zender L; Wirth T; Schulte B; Trautwein C; Manns M; Kubicka S
Cancer Gene Ther; 2004 Jan; 11(1):28-40. PubMed ID: 14681724
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer.
Wang ZX; Bian HB; Yang JS; De W; Ji XH
Cancer Biol Ther; 2009 Aug; 8(15):1480-8. PubMed ID: 19571664
[TBL] [Abstract][Full Text] [Related]
20. TATA-binding protein and the Gal4 transactivator do not bind to promoters cooperatively.
Xie Y; Sun L; Kodadek T
J Biol Chem; 2000 Dec; 275(52):40797-803. PubMed ID: 11006288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
